Glial Brain Tumors: Antiangiogenic Therapy

  • William P. J. LeendersEmail author
  • Pieter Wesseling
Part of the Methods of Cancer Diagnosis, Therapy and Prognosis book series (HAYAT, volume 8)


Although glial brain tumors have a relatively low incidence, they are among the most lethal tumors for which still no effective therapies are available. In this chapter we give an overview of clinicopathological aspects of this tumor and the mechanisms that this tumor type uses to escape available (targeted) therapies.


Epidermal Growth Factor Receptor Blood Brain Barrier Antiangiogenic Therapy Oligodendroglial Tumor Diffuse Glioma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Ali, S.A., McHayleh, W.M., Ahmad, A., Sehgal, R., Braffet, M., Rahman, M., Bejjani, G., and Friedland, D.M. (2008) Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases. J. Neurosurg. 109:268–272PubMedCrossRefGoogle Scholar
  2. Batchelor, T.T., Sorensen, A.G., di Tomaso, E., Zhang, W.T., Duda, D.G., Cohen, K.S., Kozaki, K.R., Cahill, D.P., Chen, P.J., Zhu, M., Ancukiewicz, M., Mrugala, M.M., Plotkin, S., Drappatz, J., Louis, D.N., Ivy, P., Scadden, D.T., Benner, T., Loeffier, J.S., Wen, P.Y., and Jain, R.K. (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83–95PubMedCrossRefGoogle Scholar
  3. Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E., and Hanahan, D. (2003) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111:1287–1295PubMedGoogle Scholar
  4. Canoll, P., and Goldman, J.E. (2008) The interface between glial progenitors and gliomas. Acta Neuropathol. 116:465–477PubMedCrossRefGoogle Scholar
  5. Chan, A.Y., Coniglio, S.J., Chuang, Y.Y., Michaelson, D., Knaus, U.G., Philips, M.R., and Symons, M. (2005) Roles of the Rac1 and Rac3 GTPases in human tumor cell invasion. Oncogene 24:7821–7829PubMedCrossRefGoogle Scholar
  6. Chi, A., Norden, A.D., and Wen, P.Y. (2007) Inhibition of angiogenesis and invasion in malignant gliomas. Expert Rev. Anticancer Ther. 7:1537–1560PubMedCrossRefGoogle Scholar
  7. Claes, A., and Leenders, W. (2008) Vessel normalization by VEGF inhibition. Cancer Biol. Ther. 7:7CrossRefGoogle Scholar
  8. Claes, A., Gambarota, G., Hamans, B., van Tellingen, O., Wesseling, P., Maass, C., Heerschap, A., and Leenders, W. (2008a) Magnetic resonance imaging-based detection of glial brain tumors in mice after antiangiogenic treatment. Int. J. Cancer 122:1981–1986PubMedCrossRefGoogle Scholar
  9. Claes, A., Schuuring, J., Boots-Sprenger, S., Hendriks-Cornelissen, S., Dekkers, M., van der Kogel, A.J., Leenders, W.P., Wesseling, P., and Jeuken, J.W. (2008b) Phenotypic and genotypic characterization of orthotopic human glioma models and its relevance for the study of anti-glioma therapy. Brain Pathol. 18:423–433PubMedCrossRefGoogle Scholar
  10. Claes, A., Wesseling, P., Jeuken, J., Maass, C., Heerschap, A., and Leenders, W.P. (2008c) Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization. Mol. Cancer Ther. 7:71–78PubMedCrossRefGoogle Scholar
  11. Duda, D.G., Jain, R.K., and Willett, C.G. (2007) Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J. Clin. Oncol. 25:4033–4042PubMedCrossRefGoogle Scholar
  12. Dvorak, A.M., and Feng, D. (2001) The vesiculo-vacuolar organelle (VVO). A new endothelial cell permeability organelle. J. Histochem. Cytochem. 49:419–432PubMedCrossRefGoogle Scholar
  13. Folkman, J. (1971) Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285:1182–1186PubMedCrossRefGoogle Scholar
  14. Gambarota, G., Leenders, W., Maass, C., Wesseling, P., van der Kogel, A., van Tellingen, O., and Heerschap, A. (2008) Characterization of tumor vasculature in mouse brain by USPIO contrast-enhanced MRI. Br. J. Cancer 98:1784–1789PubMedCrossRefGoogle Scholar
  15. Goldbrunner, R.H., Wagner, S., Roosen, K., and Tonn, J.C. (2000) Models for assessment of angiogenesis in gliomas. J. Neurooncol. 50:53–62PubMedCrossRefGoogle Scholar
  16. Gomez-Manzano, C., Holash, J., Fueyo, J., Xu, J., Conrad, C.A., Aldape, K.D., de Groot, J.F., Bekele, B.N., and Yung, W.K. (2008) VEGF Trap induces antiglioma effect at different stages of disease. Neuro. Oncol. 10:940–945PubMedCrossRefGoogle Scholar
  17. Groves, M.D., Puduvalli, V.K., Chang, S.M., Conrad, C.A., Gilbert, M.R., Tremont-Lukats, I.W., Liu, T.J., Peterson, P., Schiff, D., Cloughesy, T.F., Wen, P.Y., Greenberg, H., Abrey, L.E., DeAngelis, L.M., Hess, K.R., Lamborn, K.R., Prados, M.D., and Yung, W.K. (2007) A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J. Neurooncol. 81:271–277PubMedCrossRefGoogle Scholar
  18. Guha, A., Dashner, K., Black, P.M., Wagner, J.A., and Stiles, C.D. (1995) Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. Int. J. Cancer 60:168–173PubMedCrossRefGoogle Scholar
  19. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., Ferrara, N., Fyfe, G., Rogers, B., Ross, R., and Kabbinavar, F. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350:2335–2342PubMedCrossRefGoogle Scholar
  20. Jain, R.K. (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58–62PubMedCrossRefGoogle Scholar
  21. Jenkinson, M.D., Du Plessis, D.G., Walker, C., and Smith, T.S. (2007) Advanced MRI in the management of adult gliomas. Br. J. Neurosurg. 21:550–561PubMedCrossRefGoogle Scholar
  22. Kerbel, R.S. (2008) Tumor angiogenesis. N. Engl. J. Med. 358:2039–2049PubMedCrossRefGoogle Scholar
  23. Kusters, B., Leenders, W.P., Wesseling, P., Smits, D., Verrijp, K., Ruiter, D.J., Peters, J.P., van Der Kogel, A.J., and de Waal, R.M. (2002) Vascular endothelial growth factor-A (165) induces progression of melanoma brain metastases without induction of sprouting angiogenesis. Cancer Res. 62:341–345PubMedGoogle Scholar
  24. Kusters, B., Kats, G., Roodink, I., Verrijp, K., Wesseling, P., Ruiter, D.J., de Waal, R.M., and Leenders, W.P. (2007) Micronodular transformation as a novel mechanism of VEGF-A-induced metastasis. Oncogene 26:5808–5815PubMedCrossRefGoogle Scholar
  25. Lamszus, K., Kunkel, P., and Westphal, M. (2003) Invasion as limitation to anti-angiogenic glioma therapy. Acta Neurochir. (Suppl. 88):169–177Google Scholar
  26. Lee, C.G., Heijn, M., di Tomaso, E., Griffon-Etienne, G., Ancukiewicz, M., Koike, C., Park, K.R., Ferrara, N., Jain, R.K., Suit, H.D., and Boucher, Y. (2000) Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 60:5565–5570PubMedGoogle Scholar
  27. Leenders, W., Kusters, B., and De Waal, R. (2002) Vessel co-option: How tumors obtain blood supply in the absence of sprouting angiogenesis. Endothelium 9:83–87PubMedCrossRefGoogle Scholar
  28. Leenders, W.P., Kusters, B., Verrijp, K., Maass, C., Wesseling, P., Heerschap, A., Ruiter, D., Ryan, A., and de Waal, R. (2004) Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clin. Cancer Res. 10:6222–6230PubMedCrossRefGoogle Scholar
  29. Louis, D.N., Ohgaki, H., Wiestler, O.D., and Cavenee, W.K. (2007) Classification of tumours of the central nervous system. IARC Press, LyonGoogle Scholar
  30. Macdonald, D.R., Cascino, T.L., Schold, S.C. Jr., and Cairncross, J.G. (1990) Response criteria for phase II studies of supratentorial malignant glioma. J. Clin. Oncol. 8:1277–1280PubMedGoogle Scholar
  31. Martens, T., Schmidt, N.O., Eckerich, C., Fillbrandt, R., Merchant, M., Schwall, R., Westphal, M., and Lamszus, K. (2006) A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin. Cancer Res. 12:6144–6152PubMedCrossRefGoogle Scholar
  32. Mathews, M.S., Linskey, M.E., Hasso, A.N., and Fruehauf, J.P. (2008) The effect of bevacizumab (Avastin) on neuroimaging of brain metastases. Surg. Neurol. 7:7Google Scholar
  33. Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E.A., Shenkier, T., Cella, D., and Davidson, N.E. (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357:2666–2676PubMedCrossRefGoogle Scholar
  34. Motzer, R.J., Hutson, T.E., Tomczak, P., Michaelson, M.D., Bukowski, R.M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S.T., Chen, I., Bycott, P.W., Baum, C.M., and Figlin, R.A. (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356:115–124PubMedCrossRefGoogle Scholar
  35. Narayana, A., Kelly, P., Golfinos, J., Parker, E., Johnson, G., Knopp, E., Zagzag, D., Fischer, I., Raza, S., Medabalmi, P., Eagan, P., and Gruber, M.L. (2008) Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J. Neurosurg. published online October 3, 2008. doi:10.3171/2008.4.17492Google Scholar
  36. Norden, A.D., Drappatz, J., and Wen, P.Y. (2008) Antiangiogenic therapy in malignant gliomas. Curr. Opin. Oncol. 20:652–661PubMedCrossRefGoogle Scholar
  37. Prados, M.D., Lamborn, K., Yung, W.K., Jaeckle, K., Robins, H.I., Mehta, M., Fine, H.A., Wen, P.Y., Cloughesy, T., Chang, S., Nicholas, M.K., Schiff, D., Greenberg, H., Junck, L., Fink, K., Hess, K., and Kuhn, J. (2006) A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium Study. Neuro. Oncol. 8:189–193PubMedCrossRefGoogle Scholar
  38. Raymond, E., Brandes, A.A., Dittrich, C., Fumoleau, P., Coudert, B., Clement, P.M., Frenay, M., Rampling, R., Stupp, R., Kros, J.M., Heinrich, M.C., Gorlia, T., Lacombe, D., and van den Bent, M.J. (2008) Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J. Clin. Oncol. 26:4659–4665PubMedCrossRefGoogle Scholar
  39. Reardon, D.A., Egorin, M.J., Quinn, J.A., Rich, J.N., Gururangan, S., Vredenburgh, J.J., Desjardins, A., Sathornsumetee, S., Provenzale, J.M., Herndon, J.E. II, Dowell, J.M., Badruddoja, M.A., McLendon. R.E., Lagattuta, T.F., Kicielinski, K.P., Dresemann, G., Sampson, J.H., Friedman, A.H., Salvado, A.J., and Friedman, H.S. (2005) Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J. Clin. Oncol. 23:9359–9368PubMedCrossRefGoogle Scholar
  40. Reardon, D.A., Nabors, L.B., Stupp, R., and Mikkelsen, T. (2008) Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin. Investig. Drugs 17:1225–1235PubMedCrossRefGoogle Scholar
  41. Rubenstein, J.L., Kim, J., Ozawa, T., Zhang, M., Westphal, M., Deen, D.F., and Shuman, M.A. (2000) Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2:306–314PubMedCrossRefGoogle Scholar
  42. Sampson, J.H., Archer, G.E., Mitchell, D.A., Heimberger, A.B., and Bigner, D.D. (2008) Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin. Immunol. 20:267–275PubMedCrossRefGoogle Scholar
  43. Sandler, A., Gray, R., Perry, M.C., Brahmer, J., Schiller, J.H., Dowlati, A., Lilenbaum, R., and Johnson, D.H. (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355:2542–2550PubMedCrossRefGoogle Scholar
  44. Stupp, R., Mason, W.P., van den Bent, M.J., Weller, M., Fisher, B., Taphoorn, M.J., Belanger, K., Brandes, A.A., Marosi, C., Bogdahn, U., Curschmann, J., Janzer, R.C., Ludwin, S.K., Gorlia, T., Allgeier, A., Lacombe, D., Cairncross, J.G., Eisenhauer, E., and Mirimanoff, R.O. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352:987–996PubMedCrossRefGoogle Scholar
  45. Stupp, R., Hegi, M.E., Gilbert, M.R., and Chakravarti, A. (2007) Chemoradiotherapy in malignant glioma: standard of care and future directions. J. Clin. Oncol. 25:4127–4136PubMedCrossRefGoogle Scholar
  46. Vredenburgh, J.J., Desjardins, A., Herndon, J.E. 2nd, Marcello, J., Reardon, D.A., Quinn, J.A., Rich, J.N., Sathornsumetee, S., Gururangan, S., Sampson, J., Wagner, M., Bailey, L., Bigner, D.D., Friedman, A.H., and Friedman, H.S. (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol. 25:4722–4729PubMedCrossRefGoogle Scholar
  47. Wedge, S.R., Ogilvie, D.J., Dukes, M., Kendrew, J., Chester, R., Jackson, J.A., Boffey, S.J., Valentine, P.J., Curwen, J.O., Musgrove, H.L., Graham, G.A., Hughes, G.D., Thomas, A.P., Stokes, E.S., Curry, B., Richmond, G.H., Wadsworth, P.F., Bigley, A.L., and Hennequin, L.F. (2002) ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 62:4645–4655PubMedGoogle Scholar
  48. Wen PY, and Kesari S (2008) Malignant gliomas in adults. N. Engl. J. Med. 359:492–507PubMedCrossRefGoogle Scholar
  49. Wen, P.Y., Yung, W.K., Lamborn, K.R., Dahia, P.L., Wang, Y., Peng, B., Abrey, L.E., Raizer, J., Cloughesy, T.F., Fink, K., Gilbert, M., Chang, S., Junck, L., Schiff, D., Lieberman, F., Fine, H.A., Mehta, M., Robins, H.I., DeAngelis, L.M., Groves, M.D., Puduvalli, V.K., Levin, V., Conrad, C., Maher, E.A., Aldape, K., Hayes, M., Letvak, L., Egorin, M.J., Capdeville, R., Kaplan, R., Murgo, A.J., Stiles, C., and Prados, M.D. (2006) Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99–08. Clin. Cancer Res. 12:4899–4907PubMedCrossRefGoogle Scholar
  50. Zuniga, R.M., Torcuator, R., Jain, R., Anderson, J., Doyle, T., Ellika, S., Schultz, L., and Mikkelsen, T. (2008) Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J. Neurooncol. doi:10.1007/s11060-008-9718-yPubMedGoogle Scholar

Copyright information

© Springer Netherlands 2011

Authors and Affiliations

  1. 1.Department of PathologyRadboud University Nijmegen Medical CentreNijmegenThe Netherlands

Personalised recommendations